Quick Answer
CAPRICOR THERAPEUTICS, INC. reported Total Revenue of $0.00 for fiscal year 2025.
CAPRICOR THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$22.27M -11.5% |
$25.18M +886.8% |
$2.55M +941.8% |
$244.9K -21.1% |
$310.2K -69.1% |
| Net Income | -$105.04M -159.6% |
-$40.47M -81.6% |
-$22.29M +23.2% |
-$29.02M -44.9% |
-$20.02M -46.6% |
-$13.66M -78.7% |
| Diluted EPS | -$2.26 -96.5% |
-$1.15 -38.6% |
-$0.83 +29.7% |
-$1.18 -35.6% |
-$0.87 +1.1% |
-$0.88 |
| Total Assets | $355.95M +108.8% |
$170.48M +190.3% |
$58.73M +17.2% |
$50.09M +21.2% |
$41.33M +19.4% |
$34.62M +211.5% |
| Cash and Equivalents | $287.85M +2450.3% |
$11.29M -23.2% |
$14.69M +53.0% |
$9.60M -72.5% |
$34.89M +6.8% |
$32.67M +737.7% |
| Stockholders Equity | $305.79M +110.2% |
$145.46M +543.6% |
$22.60M +91.8% |
$11.79M -62.4% |
$31.37M +11.2% |
$28.20M +312.3% |
| R&D Expense | $84.45M +69.0% |
$49.97M +37.1% |
$36.45M +67.1% |
$21.82M +60.8% |
$13.57M +60.5% |
$8.46M +64.5% |
| Operating Income | -$108.14M -154.1% |
-$42.56M -76.8% |
-$24.08M +18.9% |
-$29.70M -41.8% |
-$20.94M -52.9% |
-$13.69M -77.0% |
| Shares Outstanding | 57.37M +25.9% |
45.58M +46.3% |
31.15M +23.4% |
25.24M +4.4% |
24.19M +17.5% |
20.58M +293.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $2.26M | -63.4% | -43.1% |
| Net Income | September 30, 2025 | -$24.57M | -95.7% | +5.2% |
| Diluted EPS | September 30, 2025 | -$0.54 | -42.1% | +5.3% |
| Total Assets | September 30, 2025 | $126.44M | +36.0% | -5.3% |
| Cash and Equivalents | September 30, 2025 | $19.51M | -71.5% | -16.1% |
| Stockholders Equity | September 30, 2025 | $83.87M | +22.9% | -20.1% |
| R&D Expense | September 30, 2025 | $20.36M | +72.4% | -7.7% |
| Operating Income | September 30, 2025 | -$26.28M | -102.0% | +5.2% |
| Shares Outstanding | September 30, 2025 | 45.72M | +13.4% | +0.0% |
- CAPRICOR THERAPEUTICS, INC. reported Total Revenue of $0.00 for fiscal year 2025.
- CAPRICOR THERAPEUTICS, INC. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- CAPRICOR THERAPEUTICS, INC. reported Net Income of -$105.04 million for fiscal year 2025.
- CAPRICOR THERAPEUTICS, INC. showed a decrease of -159.6% in Net Income compared to the prior fiscal year.
- CAPRICOR THERAPEUTICS, INC. reported Diluted EPS of $2.26 per share (loss) for fiscal year 2025.
- CAPRICOR THERAPEUTICS, INC. showed a decrease of -96.5% in Diluted EPS compared to the prior fiscal year.
- CAPRICOR THERAPEUTICS, INC. reported Total Assets of $355.95 million for fiscal year 2025.
- CAPRICOR THERAPEUTICS, INC. showed an increase of +108.8% in Total Assets compared to the prior fiscal year.
- CAPRICOR THERAPEUTICS, INC. reported Cash and Equivalents of $287.85 million for fiscal year 2025.
- CAPRICOR THERAPEUTICS, INC. showed an increase of +2450.3% in Cash and Equivalents compared to the prior fiscal year.
- CAPRICOR THERAPEUTICS, INC. reported Stockholders Equity of $305.79 million for fiscal year 2025.
- CAPRICOR THERAPEUTICS, INC. showed an increase of +110.2% in Stockholders Equity compared to the prior fiscal year.
- CAPRICOR THERAPEUTICS, INC. reported R&D Expense of $84.45 million for fiscal year 2025.
- CAPRICOR THERAPEUTICS, INC. showed an increase of +69.0% in R&D Expense compared to the prior fiscal year.
- CAPRICOR THERAPEUTICS, INC. reported Operating Income of -$108.14 million for fiscal year 2025.
- CAPRICOR THERAPEUTICS, INC. showed a decrease of -154.1% in Operating Income compared to the prior fiscal year.
- CAPRICOR THERAPEUTICS, INC. reported Shares Outstanding of 57.37 million shares for fiscal year 2025.
- CAPRICOR THERAPEUTICS, INC. showed an increase of +25.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: